Stocksigma LogoStocksigma Logo

Aurobindo Pharma Delivers Strong Q2FY27 Results With 32.5% YoY PAT Growth

Aurobindo Pharma reported its highest-ever quarterly revenue of INR 10,263 Cr in Q2FY27, up 23.9% YoY (12.2% QoQ)

Aurobindo Pharma Delivers Strong Q2FY27 Results With 32.5% YoY PAT Growth

Aurobindo Pharma Ltd 路 Press Release 路 05 Nov 2026, 1:33 am

Aurobindo Pharma Delivers Strong Q2FY27 Results With 32.5% YoY PAT Growth Aurobindo Pharma reported its highest-ever quarterly revenue of INR 10,263 Cr in Q2FY27, up 23.9% YoY (12.2% QoQ). EBITDA grew 28.5% YoY to INR 2,156 Cr with margins expanding 75 bps YoY to 21.0%. Net profit surged 32.5% YoY to INR 1,124 Cr. US revenue rose 25.2% YoY to INR 4,555 Cr, while Europe grew 27.5% YoY to INR 3,161 Cr. The company generated USD 146 million in free cash flow, held net cash of USD 189 million as of 30th Sep'26, and declared an interim dividend of INR 7.0 per share.

Original exchange filing (PDF)

More announcements from Aurobindo Pharma Ltd

All Aurobindo Pharma Ltd announcements